Optimization of levodopa therapy
- PMID: 1549199
Optimization of levodopa therapy
Abstract
While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of "normality," which can lead to toxicity. The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment. Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment. Nonpharmacologic concerns can help the Parkinson's disease patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups.
Similar articles
-
Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.Prescrire Int. 2005 Apr;14(76):51-4. Prescrire Int. 2005. PMID: 15875340
-
[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].Neurologia. 1997 Apr;12(4):145-56. Neurologia. 1997. PMID: 9235023 Clinical Trial. Spanish.
-
[Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].Srp Arh Celok Lek. 1997 Jul-Aug;125(7-8):203-6. Srp Arh Celok Lek. 1997. PMID: 9304232 Serbian.
-
Treatment of Parkinson's disease.Curr Opin Neurol Neurosurg. 1993 Jun;6(3):339-43. Curr Opin Neurol Neurosurg. 1993. PMID: 8507903 Review.
-
[Psychiatric complications of L-dopa: physiopathology and treatment].Rev Neurol. 1997 Aug;25 Suppl 2:S157-62. Rev Neurol. 1997. PMID: 9280683 Review. Spanish.
Cited by
-
When should levodopa therapy be initiated in patients with Parkinson's disease?Drugs Aging. 2007;24(4):261-73. doi: 10.2165/00002512-200724040-00001. Drugs Aging. 2007. PMID: 17432922 Review.
-
Novel oral drug formulations. Their potential in modulating adverse effects.Drug Saf. 1994 Mar;10(3):233-66. doi: 10.2165/00002018-199410030-00005. Drug Saf. 1994. PMID: 8043223 Review.
-
Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.Drugs Aging. 1998 Jun;12(6):495-514. doi: 10.2165/00002512-199812060-00007. Drugs Aging. 1998. PMID: 9638397 Review.
-
Pharmacokinetic optimisation in the treatment of Parkinson's disease.Clin Pharmacokinet. 1996 Jun;30(6):463-81. doi: 10.2165/00003088-199630060-00004. Clin Pharmacokinet. 1996. PMID: 8792058 Review.
-
Drug-induced sleep disturbances. Focus on nonpsychotropic medications.Drug Saf. 1997 Feb;16(2):133-49. doi: 10.2165/00002018-199716020-00005. Drug Saf. 1997. PMID: 9067124 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources